Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Temozolomide in aggressive pituitary adenomas and carcinomas.

Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K.

Clinics (Sao Paulo). 2012;67 Suppl 1:119-23. Review.

PMID:
22584716
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Treatment of pituitary neoplasms with temozolomide: a review.

Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E.

Cancer. 2011 Feb 1;117(3):454-62. doi: 10.1002/cncr.25413. Epub 2010 Sep 15. Review.

PMID:
20845485
[PubMed - indexed for MEDLINE]
Free Article
3.

MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.

Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R.

Pituitary. 2010 Dec;13(4):367-79. doi: 10.1007/s11102-010-0249-0. Review.

PMID:
20740317
[PubMed - indexed for MEDLINE]
4.

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T.

J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644. Epub 2010 Jul 21.

PMID:
20660056
[PubMed - indexed for MEDLINE]
5.

Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M.

Pituitary. 2012 Sep;15(3):276-87. doi: 10.1007/s11102-011-0363-7. Review.

PMID:
22076588
[PubMed - indexed for MEDLINE]
6.

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.

Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M.

Eur J Endocrinol. 2010 Dec;163(6):843-51. doi: 10.1530/EJE-10-0629. Epub 2010 Sep 24.

PMID:
20870708
[PubMed - indexed for MEDLINE]
Free Article
7.

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E.

Cancer. 2009 Mar 1;115(5):1070-80. doi: 10.1002/cncr.24053.

PMID:
19156926
[PubMed - indexed for MEDLINE]
Free Article
8.

MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV.

J Neurooncol. 2011 Sep;104(3):647-57. doi: 10.1007/s11060-011-0532-6. Epub 2011 Feb 11.

PMID:
21311951
[PubMed - indexed for MEDLINE]
9.

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T.

Clin Endocrinol (Oxf). 2012 Jun;76(6):769-75. doi: 10.1111/j.1365-2265.2012.04381.x. Review.

PMID:
22404748
[PubMed - indexed for MEDLINE]
10.

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.

McCormack AI, Wass JA, Grossman AB.

Eur J Clin Invest. 2011 Oct;41(10):1133-48. doi: 10.1111/j.1365-2362.2011.02520.x. Epub 2011 Apr 18.

PMID:
21496012
[PubMed - indexed for MEDLINE]
11.

DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.

Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A.

J Clin Endocrinol Metab. 2013 Mar;98(3):1130-6. doi: 10.1210/jc.2012-2924. Epub 2013 Jan 30.

PMID:
23365123
[PubMed - indexed for MEDLINE]
12.

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.

Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2009 Oct-Dec;8(4):303-6.

PMID:
20045804
[PubMed - indexed for MEDLINE]
Free Article
13.

Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.

Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2011 Apr-Jun;10(2):162-7.

PMID:
21724542
[PubMed - indexed for MEDLINE]
Free Article
14.

Use of temozolomide in aggressive pituitary tumors: case report.

Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD.

Neurosurgery. 2009 Apr;64(4):E773-4; discussion E774. doi: 10.1227/01.NEU.0000339115.12803.4E.

PMID:
19349807
[PubMed - indexed for MEDLINE]
15.

MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.

Zuhur SS, Tanik C, Karaman Ö, Velet S, Çil E, Öztürk FY, Özkayalar H, Müslüman AM, Altuntaş Y.

Endocrine. 2011 Oct;40(2):222-7. doi: 10.1007/s12020-011-9485-y. Epub 2011 May 15.

PMID:
21792693
[PubMed - indexed for MEDLINE]
16.

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.

Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M.

Eur J Endocrinol. 2009 Oct;161(4):631-7. doi: 10.1530/EJE-09-0389. Epub 2009 Aug 4.

PMID:
19654234
[PubMed - indexed for MEDLINE]
Free Article
17.

Treatment of pituitary neoplasms with temozolomide: A review.

Marucci G.

Cancer. 2011 Sep 1;117(17):4101-2; author reply 4102. doi: 10.1002/cncr.26000. Epub 2011 Mar 8. No abstract available.

PMID:
21387270
[PubMed - indexed for MEDLINE]
Free Article
18.

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.

McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ.

Clin Endocrinol (Oxf). 2009 Aug;71(2):226-33. doi: 10.1111/j.1365-2265.2008.03487.x. Epub 2008 Dec 3.

PMID:
19067722
[PubMed - indexed for MEDLINE]
19.

Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.

Curtò L, Torre ML, Ferraù F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavò S.

ScientificWorldJournal. 2010 Nov 4;10:2132-8. doi: 10.1100/tsw.2010.210. Review.

PMID:
21057727
[PubMed - indexed for MEDLINE]
Free Article
20.

Temozolomide and pituitary adenoma.

Hueng DY, Ma HI, Sytwu HK, Liu MY.

J Neurosurg. 2011 Jun;114(6):1820: author reply 1820-1. doi: 10.3171/2011.3.JNS11361. Epub 2011 Apr 22. No abstract available.

PMID:
21513431
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk